Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer

Salivary duct carcinoma is an aggressive malignancy with a high mortality rate, which phenotypically resembles high-grade breast ductal carcinoma. The parotid gland is the most common location. Standard treatment is surgery to the primary tumour together with post-operative radiotherapy. Despite this, there is a high rate of local recurrence, cervical nodal involvement and distant metastasis. Chemotherapy is currently considered only for end-stage, disseminated disease; however, current evidence indicates that chemotherapy used with radiotherapy may result in improved disease control and survival.Human epidermal growth factor receptor-2 is a proto-oncogene which is over-expressed in both breast ductal carcinoma and salivary duct carcinoma. Clinical studies of patients with metastatic breast cancer, using trastuzumab, a monoclonal antibody directed against human epidermal growth factor receptor-2, have shown significant efficacy in tumour response, resulting in improved survival. Such advances in immunohistochemistry, and in targeted immunotherapy for breast ductal carcinoma, should be applied to the treatment of salivary duct carcinoma.

show abstract

“…58,59 One argument is to consider adjuvant therapy following surgery, perhaps initially in combination with radiotherapy.…”

Section: Prognostic Indicatorsmentioning

confidence: 99%

Salivary duct carcinoma: what is already known, and can we improve survival?

2012

View full text Add to dashboard Cite

show abstract

“…Benefits of endocrine therapy in breast cancer by targeting sex steroid hormone receptor, its potential role in HNC are also tried and results of completed clinical trials are eagerly awaited [41]. Recent study conducted on tongue carcinomas demonstrated that ER antagonist interferes with cell adhesion and ultimately results in cell death which further prevents growth and progression of tumor [42].…”

Section: Clinical Implications Of Head and Neck Cancermentioning

confidence: 99%

Carcinogenesis and Sex Hormones: A Review

Bhateja¹

2015

Endocrinol Metab Syndr

View full text Add to dashboard Cite

Carcinogenesis has a multifactorial etiology. The underlying molecular pathogenesis is still poorly understood. Apart from major risk factors like tobacco, alcohol, infections, there have been some recent and less known factors like endocrine hormones. Sex hormones receptors lie outside sex organs in organs like larynx and lungs where they play a role in gene expression involved in lot of physiological and neoplastic processes. The present article is an attempt to highlight role of various sex hormones in development of carcinogenesis, particularly Head and Neck cancers (HNC).

show abstract

“…Surgery and-in patients with adverse risk factors-adjuvant radiation remain the therapeutic standard in the primary treatment of salivary gland cancer [5]. Beyond that, there is no evidence that systemic chemotherapy prolongs or improves survival [6,7]. The same holds true for molecular targeted therapy where, until now, no biological therapy has been established for the treatment of salivary gland cancer.…”

Section: Introductionmentioning

confidence: 97%

Prognostic value of proliferating cell nuclear antigen in parotid gland cancer

Stenner

Demgensky

Molls

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Although cell proliferation is related to tumour aggressiveness and prognosis, there are few studies describing the expression of proliferative markers in salivary gland cancer. Our aim was to assess the long-term prognostic value of the proliferating cell nuclear antigen (PCNA) in a large group of histologically different salivary gland cancers. We analysed the expression of PCNA in 159 patients with parotid gland cancer by means of immunohistochemistry. The mean follow-up time was 56.6 months. A high expression of PCNA showed a significant correlation to the patients' pathological lymph node stage (p = 0.004). A high PCNA expression significantly indicated a poor 5-year disease-free (p = 0.046) and overall survival rate (p = 0.018). The PCNA expression was the only prognostic factor for a worse 5-year disease-free and overall survival in acinic cell carcinomas (p = 0.004, p = 0.022). The correlation between PCNA expression and survival probabilities of salivary gland cancer might make proliferation markers helpful tools in patient follow-up, prognosis and targeted therapy in salivary gland cancer in future.

show abstract

Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer

Cited by 70 publications

References 67 publications

Salivary duct carcinoma: what is already known, and can we improve survival?

Salivary duct carcinoma: what is already known, and can we improve survival?

Carcinogenesis and Sex Hormones: A Review

Prognostic value of proliferating cell nuclear antigen in parotid gland cancer

Contact Info

Product

Resources

About